Furthermore, the study revealed elevated levels of matrix metalloproteinase-9 (MMP9) and reduced levels of chemokine ligand 2 (CCL2) in the CSF following treatment with intrathecal mesenchymal stem cell-neural progenitors (IT MSC-NPs) in cases of progressive multiple sclerosis (PMS), indicating possible neuroprotective properties and the modulation of neuroinflammatory responses. Here, MMP9 is linked to premenstrual tension.